Home | Welcome to Contract Pharma   
Last Updated Thursday, October 2 2014
Print RSS Feed

Financial Report: AstraZeneca



Published February 2, 2012
AstraZeneca

4Q Revenues: $8.7 billion (flat)

4Q Earnings: $2.2 billion (-10%)

FY Revenues: $33.6 billion (-2%)

FY Earnings: $12.8 billion (+11%)

Comments: Crestor sales were $1.8 billion in the quarter (+11%) and $6.6 billion for the year (+13%). Symbicort sales were $839 million (+13%) in the quarter and $3.1 billion for the year (+11%). Seroquel XR sales were up 27% in the quarter and year to $398 million and $1.5 billion, respectively. Onglyza sales were up 122% in the quarter to $71 million and up 206% to $211 million for the year. Generic competition impacted Arimidex sales (-42% to $166 million in the quarter and -53% to $756 million for the year); Nexium sales (-13% to $1.2 billion in the quarter and -12% for the year to $4.4 billion); and Seloken /Toprol-XL sales (-5% in the quarter to $236 million and -20% for the year to $986 million). U.S. revenues were up 5% in the quarter and down 2% for the year. Revenue in the Rest of World was down 3% in the quarter and down 2% for the year. Revenue performance in the quarter was impacted by government price interventions and the loss of around $450 million in revenue to generic competition.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On